Arteritis: Clinical Trials

13 trials for Arteritis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 313Completed 13

Follow Arteritis: new trials by email Literature Review of Arteritis trials Research Report on Arteritis

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c. - Giant Cell Arteritis
Phase 3CompletedNovartis Pharmaceuticals1512022-09-292026-02-27
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Secukinumab 300 mg, Placebo, Secukinumab 150 mg - Giant Cell Arteritis (GCA)
Phase 3CompletedNovartis Pharmaceuticals3542021-10-062026-03-31
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO
treatment - Arteritis, Giant Cell, Blindness and Low Vision
Phase 3CompletedCentre Hospitalier Universitaire de Nice82020-02-042026-06-18
MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
Prednisone treatment, Tocilizumab treatment, Methotrexate treatment - Giant Cell Arteritis
Phase 3CompletedCentre Hospitalier Universitaire Dijon2302020-01-272026-10-30
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Upadacitinib, Corticosteroid (CS), Placebo - Giant Cell Arteritis (GCA)
Phase 3CompletedAbbVie4292019-01-242026-02-24
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
Tocilizumab - Giant Cell Arteritis
Phase 3CompletedHoffmann-La Roche32017-10-252020-09-04
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
MMF, CYC, Glucocorticoids - Takayasu Arteritis
Phase 3CompletedChinese SLE Treatment And Research Group1382017-03-162023-08-30
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis
Tocilizumab - TAKAYASU ARTERITIS
Phase 3CompletedAssistance Publique - Hôpitaux de Paris182014-06-102020-08-19
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
Tocilizumab, Prednisone, Tocilizumab Placebo - Giant Cell Arteritis
Phase 3CompletedHoffmann-La Roche2512013-07-222020-02-06
Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
corticosteroid and azathioprine, corticosteroid and placebo - MPA, PAN or EGPA With FFS=0
Phase 3CompletedAssistance Publique - Hôpitaux de Paris1142008-05-012025-09-12
HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis
adalimumab, placebo - Giant Cell Arteritis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris692006-05-012012-07-10
Hydroxychloroquine in Giant Cell Arteritis
hydroxychloroquine/placebo - Giant Cell Arteritis
Phase 3CompletedUniversity Hospital, Toulouse752002-01-012015-10-06
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
Alendronate versus alfacalcidol (1-alpha OH vitamin D) - Rheumatoid Arthritis, Polymyalgia Rheumatica
Phase 3CompletedUMC Utrecht2002000-05-012006-11-29

Narrower conditions

Giant Cell Arteritis (10)  ·  Vasculitis (3)  ·  Polymyalgia Rheumatica (2)  ·  Takayasu Arteritis (2)  ·  Arthritis, Rheumatoid (1)  ·  Blindness (1)  ·  Churg-Strauss Syndrome (1)  ·  Granulomatosis with Polyangiitis (1)  ·  Microscopic Polyangiitis (1)  ·  Polyarteritis Nodosa (1)  ·  Polymyositis (1)  ·  Rheumatic Diseases (1)  ·  Vascular Diseases (1)  ·  Vision, Low (1)

Broader conditions

Cardiovascular Diseases (13)  ·  Skin Diseases (13)  ·  Skin Diseases, Vascular (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Vascular Diseases (12)  ·  Autoimmune Diseases (11)  ·  Brain Diseases (11)  ·  Central Nervous System Diseases (11)  ·  Cerebrovascular Disorders (11)  ·  Immune System Diseases (11)  ·  Nervous System Diseases (11)  ·  Autoimmune Diseases of the Nervous System (10)  ·  Vasculitis (10)  ·  Vasculitis, Central Nervous System (10)

Interventions

Adrenal Cortex Hormones (3)  ·  tocilizumab (3)  ·  secukinumab (2)  ·  Adalimumab (1)  ·  Azathioprine (1)  ·  Blood Specimen Collection (1)  ·  Glucocorticoids (1)  ·  Hydroxychloroquine (1)  ·  Methotrexate (1)  ·  Prednisone (1)  ·  Surveys and Questionnaires (1)  ·  Therapeutics (1)  ·  upadacitinib (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (3)  ·  Hoffmann-La Roche (2)  ·  Novartis Pharmaceuticals (2)  ·  AbbVie (1)  ·  Centre Hospitalier Universitaire Dijon (1)  ·  Centre Hospitalier Universitaire de Nice (1)  ·  Chinese SLE Treatment And Research Group (1)  ·  UMC Utrecht (1)  ·  University Hospital, Toulouse (1)

Countries

France (10)  ·  Germany (4)  ·  Belgium (3)  ·  Canada (3)  ·  Denmark (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Norway (3)  ·  Portugal (3)  ·  Spain (3)  ·  Sweden (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Australia (2)  ·  Austria (2)

Top investigators

Loic Guillevin, MD, PhD (1)  ·  Xavier Mariette, MD, PhD (1)  ·  Xinping Tian, MD (1)

Results publications

PMID 10068416, PMID 16221103, PMID 16914703, PMID 17332971, PMID 17407214, PMID 17557758, PMID 20054700, PMID 23528439, PMID 23897775, PMID 27924855, PMID 28678392, PMID 28745999, PMID 30786937, PMID 30835950, PMID 31056661, PMID 32943098, PMID 34049857, PMID 34718434, PMID 36963127, PMID 38279390, PMID 38840219, PMID 40174237, PMID 42234457

NIH funding

2016 (1), 2017 (1), 2023 (1)